Orchestra BioMed Holdings, Inc. filed an offering pursuant to S-3, with TD Cowen acting as joint book-running manager.
4 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Orchestra BioMed Holdings, Inc. filed an offering pursuant to S-3, with TD Cowen acting as joint book-running manager.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Orchestra BioMed Holdings, Inc. filed an S-3 offering with TD Cowen managing the process.1 source
- Forte Biosciences is making an offering under S-3, with TD Cowen managing the book run and SEC (Bangladesh) involved.
- Forte Biosciences filed an offering with TD Cowen managing the book run, declared effective by the SEC (Bangladesh).
Keep exploring
The entities involved
-
TD Cowen
American investment bank
-
Securities and Exchange Commission (Bangladesh)
government regulatory body overseeing the stock market
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireOrchestra BioMed Announces Pricing of $40 Million Public Offering NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),
- GlobeNewswireOrchestra BioMed Announces Proposed Public Offering NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical
- Unknown outlet
- Unknown outlet